MedTrace Logo

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

NCT05440643 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2026-05-11

No results posted yet for this study

Summary

This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.

Conditions

Interventions

BIOLOGICAL

Peanut SLIT-tablet

Peanut extract

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Edwin Kim, MD · University of North Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-07
Primary Completion
2026-03-10
Completion
2026-04-05
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05440643 on ClinicalTrials.gov